
-
2008
Company Description
Pathway Therapeutics develops selective inhibitors of PI3-kinase for the treatment of cancer and inflammatory diseases.
Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.
-
Manufacturer:
Science and Engineering -
Formed:
2008 -
Company Website:
-
Company E-mail:
-
Company Address:
409 Illinois StreetSan Francisco, CAUnited States -
CEO:
- Julie Cherrington
-
We recognize our sponsors starting at $1 per entry.
Learn more at https://www.ithistory.org/benefits